This site is intended for healthcare professionals

Novo Nordisk to enter phase III development in Alzheimer’s disease with oral semaglutide.

Read time: 1 mins
Last updated:17th Dec 2020
Published:17th Dec 2020
Condition: Alzheimers
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest